U.S. Markets closed

Revance Therapeutics Inc (RVNC) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Revance Therapeutics Inc (RVNC) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Revance Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. Revance Therapeutics Inc has a market cap of $626.360 million; its shares were traded at around $16.94 with and P/S ratio of 188.22. Revance Therapeutics Inc had annual average EBITDA growth of 21.60% over the past five years.


For the last quarter Revance Therapeutics Inc reported a revenue of $0.49 million, compared with the revenue of $0.04 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $3.73 million, an increase of 1323.3% from last year. For the last five years Revance Therapeutics Inc had an average revenue growth rate of 25.2% a year.

The reported loss per diluted share was $3.94 for the year, compared with the loss per share of $3.24 in the previous year. The Revance Therapeutics Inc had an operating margin of -3824.99%, compared with the operating margin of -44846.18% a year before. The 10-year historical median operating margin of Revance Therapeutics Inc is -13590.08%. The profitability rank of the company is 2 (out of 10).

At the end of the fiscal year, Revance Therapeutics Inc has the cash and cash equivalents of $73.3 million, compared with $282.9 million in the previous year. The company had no long term debt. Revance Therapeutics Inc has a financial strength rank of 8 (out of 10).

At the current stock price of $16.94, Revance Therapeutics Inc is traded at 87.8% discount to its historical median P/S valuation band of $138.38. The P/S ratio of the stock is 188.22, while the historical median P/S ratio is 1537.50. The stock lost 45.27% during the past 12 months.

CEO Recent Trades:

  • CEO and President L Daniel Browne sold 5,446 shares of RVNC stock on 02/19/2019 at the average price of $17.68. The price of the stock has decreased by 4.19% since.

For the complete 20-year historical financial data of RVNC, click here.

This article first appeared on GuruFocus.